|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CEACAM1 |
Gene summary for CEACAM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CEACAM1 | Gene ID | 634 |
| Gene name | CEA cell adhesion molecule 1 | |
| Gene Alias | BGP | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P13688 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 634 | CEACAM1 | Tumor | Human | Cervix | CC | 1.00e-03 | 2.21e-01 | 0.1241 |
| 634 | CEACAM1 | sample3 | Human | Cervix | CC | 4.21e-21 | 5.70e-01 | 0.1387 |
| 634 | CEACAM1 | H2 | Human | Cervix | HSIL_HPV | 1.56e-08 | 2.73e-01 | 0.0632 |
| 634 | CEACAM1 | T1 | Human | Cervix | CC | 2.11e-04 | 2.54e-01 | 0.0918 |
| 634 | CEACAM1 | T3 | Human | Cervix | CC | 6.61e-21 | 5.83e-01 | 0.1389 |
| 634 | CEACAM1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.56e-03 | -3.11e-01 | 0.0155 |
| 634 | CEACAM1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.45e-06 | 1.07e+00 | -0.1808 |
| 634 | CEACAM1 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.79e-02 | 1.58e+00 | -0.2602 |
| 634 | CEACAM1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.26e-07 | 1.52e+00 | -0.2196 |
| 634 | CEACAM1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.26e-03 | 6.21e-01 | -0.059 |
| 634 | CEACAM1 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.86e-03 | -8.34e-02 | 0.096 |
| 634 | CEACAM1 | A015-C-203 | Human | Colorectum | FAP | 2.52e-04 | -1.81e-01 | -0.1294 |
| 634 | CEACAM1 | A002-C-203 | Human | Colorectum | FAP | 1.70e-02 | -1.56e-01 | 0.2786 |
| 634 | CEACAM1 | A002-C-205 | Human | Colorectum | FAP | 1.38e-05 | -2.65e-01 | -0.1236 |
| 634 | CEACAM1 | A015-C-006 | Human | Colorectum | FAP | 2.10e-02 | -9.96e-02 | -0.0994 |
| 634 | CEACAM1 | A002-C-114 | Human | Colorectum | FAP | 4.08e-02 | -1.64e-01 | -0.1561 |
| 634 | CEACAM1 | A015-C-104 | Human | Colorectum | FAP | 1.15e-06 | -1.78e-01 | -0.1899 |
| 634 | CEACAM1 | A002-C-016 | Human | Colorectum | FAP | 8.73e-05 | -1.79e-01 | 0.0521 |
| 634 | CEACAM1 | A002-C-116 | Human | Colorectum | FAP | 3.65e-07 | -7.62e-02 | -0.0452 |
| 634 | CEACAM1 | A018-E-020 | Human | Colorectum | FAP | 4.70e-04 | -2.50e-01 | -0.2034 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
| GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
| GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
| GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
| GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
| GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
| GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
| GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
| GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
| GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
| GO:00071738 | Cervix | CC | epidermal growth factor receptor signaling pathway | 36/2311 | 108/18723 | 1.04e-08 | 8.44e-07 | 36 |
| GO:00071626 | Cervix | CC | negative regulation of cell adhesion | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
| GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
| GO:00381278 | Cervix | CC | ERBB signaling pathway | 37/2311 | 121/18723 | 8.57e-08 | 4.88e-06 | 37 |
| GO:00443193 | Cervix | CC | wound healing, spreading of cells | 17/2311 | 34/18723 | 9.86e-08 | 5.25e-06 | 17 |
| GO:00905053 | Cervix | CC | epiboly involved in wound healing | 17/2311 | 34/18723 | 9.86e-08 | 5.25e-06 | 17 |
| GO:00072295 | Cervix | CC | integrin-mediated signaling pathway | 34/2311 | 107/18723 | 1.01e-07 | 5.25e-06 | 34 |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CD209 | CEACAM1 | CD209_CEACAM1 | CEACAM | Breast | Healthy |
| SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | Breast | Healthy |
| CEACAM1 | CEACAM5 | CEACAM1_CEACAM5 | CEACAM | Cervix | CC |
| SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | Cervix | CC |
| CEACAM1 | CEACAM5 | CEACAM1_CEACAM5 | CEACAM | CRC | ADJ |
| CD209 | CEACAM1 | CD209_CEACAM1 | CEACAM | CRC | MSI-H |
| CEACAM1 | CEACAM5 | CEACAM1_CEACAM5 | CEACAM | CRC | MSI-H |
| CEACAM1 | CEACAM5 | CEACAM1_CEACAM5 | CEACAM | CRC | MSS |
| CD209 | CEACAM1 | CD209_CEACAM1 | CEACAM | CRC | SER |
| CEACAM1 | CEACAM5 | CEACAM1_CEACAM5 | CEACAM | CRC | SER |
| CEACAM1 | CEACAM5 | CEACAM1_CEACAM5 | CEACAM | Esophagus | ADJ |
| SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | Esophagus | ESCC |
| CEACAM1 | CEACAM5 | CEACAM1_CEACAM5 | CEACAM | HNSCC | ADJ |
| SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | HNSCC | ADJ |
| SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | HNSCC | Healthy |
| CD209 | CEACAM1 | CD209_CEACAM1 | CEACAM | HNSCC | OSCC |
| CEACAM1 | CEACAM5 | CEACAM1_CEACAM5 | CEACAM | HNSCC | OSCC |
| SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | HNSCC | OSCC |
| SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | HNSCC | Precancer |
| CEACAM1 | CEACAM5 | CEACAM1_CEACAM5 | CEACAM | Lung | MIAC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CEACAM1 | SNV | Missense_Mutation | novel | c.1110N>C | p.Glu370Asp | p.E370D | P13688 | protein_coding | tolerated(0.67) | benign(0.05) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| CEACAM1 | insertion | Nonsense_Mutation | novel | c.592_593insCTTAGTTGGTTTTTTTTGGTT | p.Arg198delinsThrTerLeuValPhePheGlyTrp | p.R198delinsT*LVFFGW | P13688 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| CEACAM1 | deletion | Frame_Shift_Del | novel | c.235delN | p.Ile79LeufsTer2 | p.I79Lfs*2 | P13688 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CEACAM1 | SNV | Missense_Mutation | novel | c.1332N>G | p.Ile444Met | p.I444M | P13688 | protein_coding | tolerated(0.08) | possibly_damaging(0.605) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CEACAM1 | SNV | Missense_Mutation | rs150099950 | c.944N>T | p.Thr315Met | p.T315M | P13688 | protein_coding | tolerated(0.21) | benign(0.255) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CEACAM1 | SNV | Missense_Mutation | c.29N>C | p.Arg10Thr | p.R10T | P13688 | protein_coding | tolerated(0.06) | possibly_damaging(0.465) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CEACAM1 | SNV | Missense_Mutation | novel | c.521C>T | p.Thr174Ile | p.T174I | P13688 | protein_coding | tolerated(0.14) | possibly_damaging(0.734) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CEACAM1 | SNV | Missense_Mutation | c.1080C>A | p.Phe360Leu | p.F360L | P13688 | protein_coding | tolerated(1) | benign(0.015) | TCGA-AG-A01N-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | SD | |
| CEACAM1 | SNV | Missense_Mutation | novel | c.461C>T | p.Ser154Phe | p.S154F | P13688 | protein_coding | deleterious(0.02) | possibly_damaging(0.838) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CEACAM1 | SNV | Missense_Mutation | rs749934399 | c.89C>T | p.Pro30Leu | p.P30L | P13688 | protein_coding | tolerated(0.4) | benign(0.017) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | CHEMOKINES | 15937057 | ||
| 634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | ARCITUMOMAB | ARCITUMOMAB | ||
| 634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | RETINOID | 8609714 | ||
| 634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | RETINOIC ACID | 15364113 | ||
| 634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | ARCITUMOMAB | ARCITUMOMAB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |